RxDoctor Payments Data

Mara Schroeder, PA

Medical · Clifton Springs, NYNPI 1104483858

Payments from drug & device makers

$3,781in general payments, 2019–2025

Across 149 payments — averaging $25.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$1K
  • Medtronic$1K
  • Sanofi-aventis U.S. LLC$299
  • Tandem Diabetes Care, Inc.$176
  • Novo Nordisk$176
  • Abbott$125
  • plus $556 from 11 others

What the payments were for

  • Travel & lodging$84522%
  • Food & beverage$2,92977%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,781 in reported general payments places this provider in the 85th percentile of 2,395 medical providers in New York.

See all medical providers in New York

Medicare billing

Part B allowed, 2024
$26,325
Medicare patients
197
Services billed
407

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide614$739,914
OzempicSemaglutide476$607,632
JardianceEmpagliflozin349$401,798
TrulicityDulaglutide247$344,270
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7124$221,197
RybelsusSemaglutide40$84,633
FarxigaDapagliflozin Propanediol78$76,176
Lantus SolostarInsulin Glargine,hum.Rec.Anlog369$57,896
Humalog Kwikpen U-200Insulin Lispro13$53,721
JanuviaSitagliptin Phosphate52$50,870
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog36$47,298
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog32$46,236
Insulin Lispro Kwikpen U-100Insulin Lispro164$45,220
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog83$44,377
Tresiba Flextouch U-200Insulin Degludec22$35,059

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro$1,406$1,121,7301,017 claims
Novo NordiskOzempic, Rybelsus, Novolog$176$714,070578 claims
Boehringer IngelheimJardiance$70$401,798349 claims
AstraZenecaFarxiga$26$76,17678 claims
Cequr CorporationCequr Simplicity$6$23,79155 claims
AmgenProlia$110$21,18213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,395 medical providers in New York.

Other medical in Clifton Springs

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →